Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06455254 |
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM | 阶段
第二阶段
|
Date Added 2024-06-12 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06415851 |
TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | 阶段
第二阶段
|
Date Added 2024-05-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06412198 |
TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | 阶段
Phase 1, Phase 2
|
Date Added 2024-05-14 |
地点
Massachusetts, United States
Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Adagrasib, cemiplimab, cetuximab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2024-03-29 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | 阶段
第 1 阶段
|
Date Added 2024-03-21 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 大韩民国 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06310564 |
TitleLow and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy | 阶段
不适用
|
Date Added 2024-03-15 |
地点
意大利
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06300463 |
Title结直肠癌肝转移免疫疗法组合平台研究 | 阶段
第二阶段
|
Date Added 2024-03-08 |
地点
New York, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
AGEN1423, Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT06302062 |
TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2024-03-08 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06253520 |
TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | 阶段
第 1 阶段
|
Date Added 2024-02-12 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06218914 |
TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | 阶段
第 1 阶段
|
Date Added 2024-01-23 |
地点
California, United States
Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
